Federica Papaccio
Overview
Explore the profile of Federica Papaccio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Rosa C, Morgillo F, Amato L, Iommelli F, De Rosa V, Tirino V, et al.
iScience
. 2025 Mar;
28(3):111943.
PMID: 40034862
Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer with limited treatment options. Patients often respond well to initial chemo-immunotherapy but relapse quickly, necessitating new strategies...
2.
Papaccio F, Cabeza-Segura M, Garcia-Mico B, Gimeno-Valiente F, Zuniga-Trejos S, Gambardella V, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):77.
PMID: 40022181
Background: Chromosomal instability (CIN) is involved in about 70% of colorectal cancers (CRCs) and is associated with poor prognosis and drug resistance. From a clinical perspective, a better knowledge of...
3.
Amato L, Omodei D, De Rosa C, Ariano A, Capaldo S, Tufano C, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682133
Background: Oncogene-driven NSCLC is usually treated with targeted therapies using tyrosine kinase inhibitors (TKIs) to inhibit oncogene downstream signaling pathways, affecting tumor survival and proliferation. EGFR- and KRAS-mutant NSCLCs are...
4.
Rebaudi F, De Franco F, Goda R, Obino V, Vita G, Baronti C, et al.
Cancer Treat Rev
. 2024 Sep;
130:102831.
PMID: 39342797
This review focuses on the immune checkpoint inhibitors (ICIs) in the context of breast cancer (BC) management. These innovative treatments, by targeting proteins expressed on both tumor and immune cells,...
5.
Papaccio F, Ottaviani M, Truglio M, DArino A, Caputo S, Pacifico A, et al.
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337683
While vitiligo is primarily caused by melanocyte deficiency or dysfunction, recent studies have revealed a notable prevalence of metabolic syndrome (MetS) among patients with vitiligo. This suggests shared pathogenic features...
6.
Greppi M, De Franco F, Obino V, Rebaudi F, Goda R, Frumento D, et al.
Immunol Lett
. 2024 Sep;
270:106932.
PMID: 39303993
Natural Killer (NK) cells are integral to the innate immune system, renowned for their ability to target and eliminate cancer cells without the need for antigen presentation, sparing normal tissues....
7.
Russo F, Pira A, Mariotti F, Papaccio F, Giampetruzzi A, Bellei B, et al.
Front Immunol
. 2024 Sep;
15:1416473.
PMID: 39267741
Bullous pemphigoid (BP) is the most common autoimmune bullous disease: it most commonly affects individuals over 70 years old and impacts severely on their quality of life. BP represents a...
8.
Rehman A, Marigliano M, Torsiello M, La Noce M, Papaccio G, Tirino V, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123496
Adipose-derived stem cells (ASCs) significantly influence tumor progression within the tumor microenvironment (TME). This review examines the pro-tumorigenic roles of ASCs, focusing on paracrine signaling, direct cell-cell interactions, and immunomodulation....
9.
Del Vecchio V, Rehman A, Panda S, Torsiello M, Marigliano M, Nicoletti M, et al.
J Exp Clin Cancer Res
. 2024 Jun;
43(1):166.
PMID: 38877575
Background: Breast cancer (BC) is a complex disease, showing heterogeneity in the genetic background, molecular subtype, and treatment algorithm. Historically, treatment strategies have been directed towards cancer cells, but these...
10.
De Rosa C, Iommelli F, De Rosa V, Ercolano G, Sodano F, Tuccillo C, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672164
Background: Lung cancer (LC), including both non-small (NSCLC) and small (SCLC) subtypes, is currently treated with a combination of chemo- and immunotherapy. However, predictive biomarkers to identify high-risk patients are...